The Latest Breaking News from JNJ

Johnson & Johnson, Distributors Reach $590M Opioid Settlement For Tribe Claims: Report

Johnson & Johnson (NYSE: JNJ) and the three U.S.

Benzinga · Feb 2, 2022

4 Dividend Aristocrats to Buy in February

Rising inflation and the Fed’s signal that it will raise interest rates multiple times this year fostered high market volatility last month. And although the major market indexes rose for the third consecutive trading session yesterday, many analysts expect the market to remain volatile this year. Given this backdrop, we…

StockNews.com · Feb 2, 2022

Johnson & Johnson Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Johnson & Johnson (NYSE:JNJ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · Jan 31, 2022

Johnson & Johnson's Earnings: A Preview

Johnson & Johnson (NYSE:JNJ) is set to give its latest quarterly earnings report on Tuesday, 2022-01-25. Here's what investors need to know before the announcement. Analysts estimate that Johnson & Johnson will likely report an Earnings Per Share (EPS) of $2.12.

Benzinga · Jan 24, 2022

3 Pharmaceutical Stocks to Buy for the Long-Term

The global pharmaceutical industry is expected to witness stable growth over the long term, owing to the rising medical needs of an aging population and consistent innovations in the treatment of chronic ailments. So, we think it could be wise to scoop up shares of quality pharmaceutical stocks Johnson &…

StockNews.com · Jan 21, 2022

Best Dividend Kings for Decades of Dividend Growth

Dividend Kings are the crème de la crème of dividend growers and should be top of mind for any investor who puts income stability above all else.

Kiplinger · Mar 1, 2021